Identification
- Summary
Cetrimonium is a compound that can be used as a topical antiseptic.
- Brand Names
- Xylonor
- Generic Name
- Cetrimonium
- DrugBank Accession Number
- DB01718
- Background
Cetrimonium is a quaternary ammonium cation whose salts are used as antiseptics.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cetrimonium (DB01718)
- Weight
- Average: 284.5435
Monoisotopic: 284.331725349 - Chemical Formula
- C19H42N
- Synonyms
- Cetrimonium cation
- Cetrimonium ion
- Cetyl-Trimethyl-Ammonium
- Cetyltrimethylammonium
- Cetyltrimethylammonium cation
- Cetyltrimethylammonium ion
- Hexadecyltrimethylammonium
- Hexadecyltrimethylammonium cation
- Hexadecyltrimethylammonium ion
- N,N,N-Trimethyl-1-hexadecanaminium
- Trimethylhexadecylammonium
- External IDs
- PB-300
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Burns Combination Product in combination with: Benzalkonium (DB11105) ••• ••• •••••••• ••••• Used in combination to treat Diaper rash Combination Product in combination with: Benzalkonium (DB11105) ••• ••• ••••• Treatment of Diaper rash ••• ••• •••••• ••••••• ••••••• ••••••••• •••••••• Prevention of Diaper rash ••• ••• •••••• ••••••• ••••••• ••••••••• •••••••• Used in combination for symptomatic treatment of Inflammatory reaction of the oral mucosa Combination Product in combination with: Lidocaine (DB00281), Tyrothricin (DB13503) ••• ••• ••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCyclopropane mycolic acid synthase 1 Not Available Mycobacterium tuberculosis UCyclopropane mycolic acid synthase MmaA2 Not Available Mycobacterium tuberculosis - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cetrimonium bromide L64N7M9BWR 57-09-0 LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium carboxydecyl PEG-8 dimethicone 0T3143V100 Not Available Not applicable Cetrimonium chloride UC9PE95IBP 112-02-7 WOWHHFRSBJGXCM-UHFFFAOYSA-M Cetrimonium hydroxide 8Q7D6895LV 505-86-2 WJLUBOLDZCQZEV-UHFFFAOYSA-M - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cetrimide Aqueous Soln 1% Liquid 1 % Topical Ingram And Bell Inc. 1960-12-31 1999-08-05 Canada 
Cetrimide Cream 0.5% Cream .5 % Topical Canadian Custom Packaging Company 1992-12-31 Not applicable Canada Cetrimide Tincture 0.5% Tincture .5 % Topical Canadian Custom Packaging Company 1990-12-31 Not applicable Canada CETRIX CREAM 0.5% Cream Topical PRIME PHARMACEUTICAL SDN. BHD. 2020-09-08 Not applicable Malaysia 
Derma Wound-Eaz Cream 5 mg/1g Topical Pella Pharmaceuticals Co. ltd 2022-10-31 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AXCEL SILICONE CREAM BPC 73 Cetrimonium bromide (0.5 %) + Dimethicone (10 %) Cream Topical KOTRA PHARMA (M) SDN. BHD. 2020-09-08 2020-12-18 Malaysia BACTRICIDE Cetrimonium bromide (15 g/100mL) + Chlorhexidine gluconate (1.5 g/100mL) Solution Topical บริษัท สหแพทย์เภสัช จำกัด 1997-05-20 Not applicable Thailand 
Bye Bye Burn Lot Cetrimonium bromide (.1 %) + Allantoin (.1 %) + Benzocaine (.55 %) + Vitamin E (2 %) Lotion Topical David D. Daniels Ltd. 1996-08-15 1998-01-15 Canada CHLORHEXIDINE GLUCONATE-CETRIMIDE SOLUTION Cetrimonium bromide (15 g/100mL) + Chlorhexidine gluconate (1.5 g/100mL) Solution Topical บริษัท บี.เอ็ล.ฮั้ว จำกัด จำกัด 1986-05-29 Not applicable Thailand Chlorhexidine-cetrimide Soltn Conc Cetrimonium bromide (15 %) + Chlorhexidine gluconate (1.5 %) Liquid Topical Bio Pharm, Inc. 1989-12-31 1996-09-09 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Derma Wound-Eaz Cetrimonium bromide (5 mg/1g) Cream Topical Pella Pharmaceuticals Co. ltd 2022-10-31 Not applicable US Dr. Zheng bacteriostatic solution Cetrimonium bromide (0.125 mg/100mL) Liquid Extracorporeal Guangzhou Yuxiao Biological Products Co., Ltd 2020-04-11 Not applicable US
Categories
- ATC Codes
- D08AJ04 — Cetrimide
- D08AJ — Quaternary ammonium compounds
- D08A — ANTISEPTICS AND DISINFECTANTS
- D08 — ANTISEPTICS AND DISINFECTANTS
- D — DERMATOLOGICALS
- D11AC — Medicated shampoos
- D11A — OTHER DERMATOLOGICAL PREPARATIONS
- D11 — OTHER DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- Drug Categories
- Amines
- Anti-Infective Agents
- Anti-Infective Agents, Local
- Antiseptics and Disinfectants
- Cetrimonium Compounds
- Compounds used in a research, industrial, or household setting
- Dermatologicals
- Medicated Shampoos
- Miscellaneous Local Anti-infectives
- Onium Compounds
- Quaternary Ammonium Compounds
- Throat Preparations
- Trimethyl Ammonium Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tetraalkylammonium salts. These are organonitrogen compounds containing a quaternary ammonium substituted with four alkyl chains.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Quaternary ammonium salts
- Direct Parent
- Tetraalkylammonium salts
- Alternative Parents
- Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Amines / Organic cations
- Substituents
- Aliphatic acyclic compound / Amine / Hydrocarbon derivative / Organic cation / Organic salt / Organopnictogen compound / Tetraalkylammonium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- quaternary ammonium ion (CHEBI:39561) / a cation (CPD-13595)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z7FF1XKL7A
- CAS number
- 6899-10-1
- InChI Key
- RLGQACBPNDBWTB-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H42N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4/h5-19H2,1-4H3/q+1
- IUPAC Name
- hexadecyltrimethylazanium
- SMILES
- CCCCCCCCCCCCCCCC[N+](C)(C)C
References
- General References
- Not Available
- External Links
- KEGG Drug
- D03454
- KEGG Compound
- C11275
- PubChem Compound
- 2681
- PubChem Substance
- 46507665
- ChemSpider
- 2580
- BindingDB
- 58941
- 20614
- ChEBI
- 39561
- ChEMBL
- CHEMBL1183605
- ZINC
- ZINC000006846023
- PDBe Ligand
- 16A
- Wikipedia
- Cetrimonium
- PDB Entries
- 1kpg / 1tpy / 3b00 / 3hf0 / 3p73 / 5hxw / 6wl5 / 7jj1
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Unknown Status Treatment Local Anaesthesia therapy / Wounds Injuries 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Lotion Topical Ointment Solution Topical Solution, concentrate Topical Liquid Topical 1 % Tincture Topical .5 % Solution Vaginal 100 ml Solution Vaginal 1000 ml Solution Vaginal 500 ml Shampoo Topical Cream Topical 5 mg/1g Cream Cutaneous 1.000 g Cream Topical Cream Topical Liquid Extracorporeal 0.125 mg/100mL Cream Cutaneous Spray Transmucosal Lozenge Oral Liquid; shampoo Topical 1 % Cream Topical .5 % Liquid Topical Gel Topical Gel Topical 0.5 % w/w Lotion Spray, metered Buccal Spray, metered Topical Spray Oral Aerosol Topical Aerosol, metered Buccal Spray Topical 0.15 g/100g Solution Vaginal Cream Topical 0.5 %w/w Gel Ophthalmic Liquid Dental Solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 240 °C PhysProp water solubility 1E+005 mg/L MERCK INDEX (1996) - Predicted Properties
Property Value Source Water Solubility 5.24e-06 mg/mL ALOGPS logP 2.48 ALOGPS logP 2.69 Chemaxon logS -7.8 ALOGPS Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 104.99 m3·mol-1 Chemaxon Polarizability 41.09 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8956 Blood Brain Barrier + 0.9693 Caco-2 permeable + 0.7014 P-glycoprotein substrate Non-substrate 0.5098 P-glycoprotein inhibitor I Non-inhibitor 0.9556 P-glycoprotein inhibitor II Non-inhibitor 0.7862 Renal organic cation transporter Non-inhibitor 0.6184 CYP450 2C9 substrate Non-substrate 0.8557 CYP450 2D6 substrate Non-substrate 0.6596 CYP450 3A4 substrate Substrate 0.5059 CYP450 1A2 substrate Non-inhibitor 0.8243 CYP450 2C9 inhibitor Non-inhibitor 0.947 CYP450 2D6 inhibitor Non-inhibitor 0.9149 CYP450 2C19 inhibitor Non-inhibitor 0.9266 CYP450 3A4 inhibitor Non-inhibitor 0.9831 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9722 Ames test Non AMES toxic 0.9617 Carcinogenicity Carcinogens 0.7243 Biodegradation Ready biodegradable 0.8286 Rat acute toxicity 2.8455 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8233 hERG inhibition (predictor II) Non-inhibitor 0.5139
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0a4i-9640000000-9788151c24f58600b647 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 177.60329 predictedDeepCCS 1.0 (2019) [M+H]+ 180.15358 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.2245 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Mycobacterium tuberculosis
- Pharmacological action
- Unknown
- General Function
- Catalyzes the conversion of a double bond to a cyclopropane ring at the distal position of an alpha mycolic acid via the transfer of a methylene group from S-adenosyl-L-methionine. Cyclopropanated mycolic acids are key factors participating in cell envelope permeability, host immunomodulation and persistence.
- Specific Function
- Cyclopropane-fatty-acyl-phospholipid synthase activity
- Gene Name
- cmaA1
- Uniprot ID
- P9WPB7
- Uniprot Name
- Cyclopropane mycolic acid synthase 1
- Molecular Weight
- 32460.98 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Mycobacterium tuberculosis
- Pharmacological action
- Unknown
- General Function
- Methyltransferase activity
- Specific Function
- Catalyzes the conversion of a double bond to a cis cyclopropane ring at the distal position of an alpha mycolic acid via the transfer of a methylene group from S-adenosyl-L-methionine. MmaA2 also c...
- Gene Name
- mmaA2
- Uniprot ID
- Q79FX6
- Uniprot Name
- Cyclopropane mycolic acid synthase MmaA2
- Molecular Weight
- 32724.06 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at April 16, 2024 12:20